Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21929873 | 0.86 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL21929874 | 0.86 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31461142 | 0.86 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29278897 | 0.86 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30018304 | 0.86 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22768638 | 0.86 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22440916 | 0.85 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22440915 | 0.85 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22749554 | 0.85 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22768493 | 0.85 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114258393-B | Heterocyclic compounds having dual inhibitory activity of phosphatidylinositol 3-kinase delta and gamma and medical uses thereof | 中国医药研究开发中心有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| CN-115677692-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114025756-B | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-114258393-A | Heterocyclic compound with dual phosphatidylinositol 3-kinase delta and gamma inhibitor activity and medical application thereof | 中国医药研究开发中心有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114025756-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.